Soleno Therapeutics Receives Breakthrough Therapy Designation From FDA For DCCR Extended-Release Tablets in Prader-Willi Syndrome
Soleno Therapeutics Inc -0.20% Pre
Soleno Therapeutics Inc SLNO | 53.64 53.64 | -0.20% 0.00% Pre |
First Ever Breakthrough Designation for a Drug Being Developed for PWS
Designation is Based on Data from the Phase 3 Program for DCCR
Planned Submission of a New Drug Application (NDA) for DCCR Remains on Track for Mid-2024